HC Wainwright set a $4.00 target price on Trevena (NASDAQ:TRVN) in a research note issued to investors on Monday, Stock Target Advisor reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on the company. Zacks Investment Research cut Trevena from a buy rating to a hold rating in a research report on Wednesday, May 15th. ValuEngine cut Trevena from a hold rating to a sell rating in a research report on Friday, May 3rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Trevena presently has an average rating of Hold and a consensus target price of $5.38.
TRVN opened at $0.99 on Monday. Trevena has a 12 month low of $0.38 and a 12 month high of $3.58. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.18. The firm has a market cap of $88.66 million, a PE ratio of -2.36 and a beta of 2.62. The firm has a 50 day simple moving average of $1.19.
Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. increased its position in Trevena by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock worth $1,147,000 after buying an additional 80,437 shares during the period. Vanguard Group Inc. increased its position in Trevena by 29.2% during the third quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock worth $5,552,000 after buying an additional 592,152 shares during the period. Geode Capital Management LLC increased its position in Trevena by 38.9% during the fourth quarter. Geode Capital Management LLC now owns 477,007 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 133,510 shares during the period. Two Sigma Advisers LP increased its position in Trevena by 35.3% during the fourth quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 16,400 shares during the period. Finally, Tibra Equities Europe Ltd acquired a new position in Trevena during the first quarter worth approximately $283,000. 23.58% of the stock is owned by hedge funds and other institutional investors.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
See Also: Overbought
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.